Fertility and sterility最新文献

{"title":"Effect of denosumab on semen quality in infertile men selected by serum level of antimüllerian hormone: a randomized controlled trial","authors":"Sam Kafai Yahyavi M.D. , Rune Holt M.D., Ph.D. , Mads Joon Jorsal M.D. , Gustav Wall-Gremstrup M.D. , Frederikke Bay Toft M.D. , Li Juel Mortensen M.D., Ph.D. , Bugge Nøhr M.D., Ph.D. , Linda Magnusson Melsen M.Sc. , Lisbeth Prætorius M.D., Ph.D. , Henriette Svarre Nielsen M.D., Ph.D. , Anja Pinborg M.D., Ph.D. , Jens-Erik Beck Jensen M.D., Ph.D. , Peter Schwarz M.D., Ph.D. , Finn Noe Bennedbæk M.D., Ph.D. , Lise Aksglaede M.D., Ph.D. , Anne Jørgensen M.Sc., Ph.D. , Niels Jørgensen M.D., Ph.D. , Jørgen Holm Petersen M.Sc., Ph.D. , Anders Juul M.D., D.M.Sc. , Martin Blomberg Jensen M.D., D.M.Sc.","doi":"10.1016/j.fertnstert.2025.05.151","DOIUrl":"10.1016/j.fertnstert.2025.05.151","url":null,"abstract":"<div><h3>Objective</h3><div>To determine whether denosumab<span><span> could improve sperm concentration in infertile men selected by serum antimüllerian hormone<span> (AMH) ≥ 38 pmol/L. Mouse models, human testicular tissue models, and clinical intervention studies have suggested that the RANKL-inhibitor </span></span>denosumab<span>, normally used to treat osteoporosis, can improve semen quality in a sub-population of infertile men.</span></span></div></div><div><h3>Design</h3><div>A double-blinded, placebo-controlled, single-center, randomized clinical trial.</div></div><div><h3>Subjects</h3><div>The study was designed to include 282 infertile men with a planned interim analysis after inclusion of 170 men.</div></div><div><h3>Intervention</h3><div>The groups were randomized 1:1 to receive either a single subcutaneous injection<span> of denosumab 60 mg or a placebo treatment for 80 days.</span></div></div><div><h3>Main Outcome Measure</h3><div>Sperm concentration.</div></div><div><h3>Results</h3><div><span>The trial was terminated after the interim analysis (n = 179), with 90 men assigned to denosumab treatment and 89 men to placebo treatment. No difference in sperm concentration was found at day 80 between denosumab and placebo-treated men (difference of –1.0 million/mL [95% CI –2.7, 1.1]). Moreover, no differences in percentages of motile, progressively motile, or morphologically normal spermatozoa were found. An interaction analysis identified a subgroup of men with testis size ≤16 mL and no history of </span>cryptorchidism who had an increase in sperm concentration of 29% (8.5 million/mL at baseline to 11.0 million/mL at day 80) after treatment with denosumab.</div></div><div><h3>Conclusions</h3><div>Denosumab did not improve semen quality in infertile men selected on the basis of their serum AMH concentrations. The positive effect of denosumab in a subgroup can only be considered exploratory and needs verification in additional prospective studies.</div></div><div><h3>Trial ID</h3><div>ClinicalTrials.gov: <span><span>NCT05212337</span><svg><path></path></svg></span>. EudraCT 2021–003451-42.</div></div><div><div>Efecto del denosumab en la calidad del semen en hombres infértiles seleccionados por su nivel sérico de hormona antimülleriana: un ensayo clínico aleatorizado y controlado</div></div><div><h3>Objetivo</h3><div>Determinar si el denosumab podría mejorar la concentración espermática en hombres infértiles seleccionados por su nivel sérico de hormona antimülleriana (AMH) ≥ 38 pmol/L. Modelos murinos, modelos de tejido testicular humano y estudios de intervención clínica han sugerido que el inhibidor de RANKL, denosumab, utilizado habitualmente para tratar la osteoporosis, puede mejorar la calidad del semen en una subpoblación de hombres infértiles.</div></div><div><h3>Diseño</h3><div>Ensayo clínico aleatorizado, doble ciego, controlado con placebo, unicéntrico.</div></div><div><h3>Pacientes</h3><div>El estudio se diseñó para incluir a 28","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 668-678"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative pretrigger progesterone levels are not superior to single-day levels for predicting a failed cycle in fresh embryo transfer cycles","authors":"Meghan Yamasaki D.O. , Kerry Flannagan Ph.D. , David Boedeker D.O. , Shelley Dolitsky M.D. , Nicole Banks M.D. , Alan Decherney M.D. , Eduardo Hariton M.D., M.B.A. , Benjamin S. Harris M.D., M.P.H. , Anthony Imudia M.D. , Caleb Kallen M.D., Ph.D. , Jessica Kanter M.D. , Michael Levy M.D. , Phillip Romanski M.D. , Meike Uhler M.D. , Kate Devine M.D. , Micah Hill D.O.","doi":"10.1016/j.fertnstert.2025.04.024","DOIUrl":"10.1016/j.fertnstert.2025.04.024","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 772-774"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study","authors":"Jacques Donnez M.D., Ph.D. , Felice Petraglia M.D. , Hugh Taylor M.D. , Christian M. Becker M.D. , Sven Becker M.D., Ph.D. , Francisco Carmona Herrera M.D., Ph.D. , Elke Bestel M.D. , Satoshi Hori M.D., Ph.D., M.B.A. , Marie-Madeleine Dolmans M.D., Ph.D.","doi":"10.1016/j.fertnstert.2025.06.016","DOIUrl":"10.1016/j.fertnstert.2025.06.016","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can maintain the efficacy and tolerability seen at 6 months of therapy and whether there is any recurrence of symptoms (bleeding and pain) after cessation of therapy (withdrawal study).</div></div><div><h3>Design</h3><div>PRIMROSE 1 and PRIMROSE 2 were essentially identical, randomized, parallel, double-blind, and placebo-controlled phase 3 trials conducted in women with uterine fibroid-associated heavy menstrual bleeding (HMB) (menstrual blood loss [MBL] of more than 80 mL per cycle over 2 menstrual cycles).</div></div><div><h3>Subjects</h3><div>In PRIMROSE 1 and 2, 1,012 women were included in the full analysis set. Eligible subjects were women aged 18 years or older with ultrasound-confirmed fibroids and HMB of at least 80 mL blood loss per cycle for a minimum of two cycles, as determined by the alkaline hematin method. Eligible participants had to have at least one fibroid measuring 2 cm in diameter or more (or multiple small fibroids with overall uterine volume exceeding 200 cm<sup>3</sup>), but no fibroids greater than 12 cm in diameter.</div></div><div><h3>Intervention</h3><div>Eligible women with uterine fibroid-associated HMB were randomly assigned at a 1:1:1:1:1 ratio to one of five masked daily treatment: placebo, 100 mg linzagolix alone, 100 mg linzagolix with hormonal ABT (1 mg estradiol and 0.5 mg norethisterone acetate), 200 mg linzagolix alone , or 200 mg linzagolix with hormonal ABT (1 mg estradiol and 0.5 mg norethisterone acetate). After 24 weeks, patients assigned to the placebo or 200 mg linzagolix alone groups were switched to 200 mg linzagolix with ABT, except in PRIMROSE 1, in which 50% of subjects on a placebo continued with the placebo (random selection) until week 52. All other women continued on the original study medication. Efficacy and safety were evaluated at week 52 (extension study) as well as week 64 (withdrawal study). Bone mineral density was also assessed at week 76 (6 months after cessation of therapy).</div></div><div><h3>Main Outcome Measures</h3><div>The primary endpoint was decreased MBL to less than 80 mL and a reduction of more than 50% from baseline. Specifically, this study sought to determine whether the reduction in MBL and other secondary outcomes, such as uterine volume and pain, observed at 24 weeks could be maintained over an extended (52 weeks) treatment period and further withdrawal period.</div></div><div><h3>Results</h3><div>In the pooled data from PRIMROSE 1 and PRIMROSE 2 extension studies, the significantly higher proportion of women showing a reduction in HMB in all linzagolix (with or without ABT) treatment groups observed at week 24, was maintained until week 52. Percentages of women with reduced MBL at week 52 (based on the pooled week","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 737-748"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infertility evaluation and treatment in cancer survivors","authors":"Jeremy Applebaum M.D.,&nbsp;Elizabeth S. Ginsburg M.D.","doi":"10.1016/j.fertnstert.2025.07.1222","DOIUrl":"10.1016/j.fertnstert.2025.07.1222","url":null,"abstract":"<div><div>As survival rates for cancer continue to rise, growing attention is being directed toward the reproductive health of female cancer survivors. This review outlines the unique considerations in evaluating and treating infertility in this population. Cancer survivors face an elevated risk of infertility relating to treatment-induced hypothalamic-pituitary dysfunction, loss of ovarian function, or non-functional or surgically absent reproductive anatomy. A comprehensive, individualized infertility evaluation is essential and should incorporate a multidisciplinary approach involving infertility specialists, oncologists, high-risk obstetricians, genetic specialists, and mental health care providers. Risk-based assessment tools may offer insight into ovarian function and may help guide fertility treatment timing. Fertility treatment options for survivors include both standard and modified ovarian stimulation protocols. The use of preimplantation genetic testing for monogenic disease, donor gametes or embryos, and gestational carriers may also be necessary. Although outcomes data remain limited, early evidence suggests that clinical pregnancy and live birth rates in this population can be favorable, particularly with personalized treatment strategies. Increased prospective research is critical to optimizing fertility care and informing evidence-based counseling for this growing population.</div></div>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 604-611"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144802539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nine lessons from the editor’s chair","authors":"Alan H. DeCherney M.D.","doi":"10.1016/j.fertnstert.2025.07.028","DOIUrl":"10.1016/j.fertnstert.2025.07.028","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 582-583"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive update on the reproductive care of patients with cancer and survivors in reproductive endocrinology practice","authors":"Elizabeth S. Ginsburg M.D.","doi":"10.1016/j.fertnstert.2025.08.018","DOIUrl":"10.1016/j.fertnstert.2025.08.018","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Page 584"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum for Combs JC, Yamasaki MU, Dougherty M, Hunkler K, Osmundsen EB, Roura-Monllor J, et al. Comparing gestational carrier with uterine transplantation in uterine-factor infertility: a cost-effectiveness analysis [Fertil Steril 2025;124:134–43]","authors":"","doi":"10.1016/j.fertnstert.2025.07.1203","DOIUrl":"10.1016/j.fertnstert.2025.07.1203","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 797-798"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular disruptions to the future fetal tissue lineage are associated with delayed euploid blastulation","authors":"Blair R. McCallie Ph.D. ,&nbsp;Michelle M. Denomme Ph.D. ,&nbsp;Mary E. Haywood Ph.D. ,&nbsp;Kalyn Trowbridge B.S. ,&nbsp;Jennifer M. Hamm M.S. ,&nbsp;Keelee J. McCarty Ph.D. ,&nbsp;William B. Schoolcraft M.D. ,&nbsp;Mandy G. Katz-Jaffe Ph.D.","doi":"10.1016/j.fertnstert.2025.06.001","DOIUrl":"10.1016/j.fertnstert.2025.06.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To study the underlying molecular activity driving the reduced reproductive potential of day 7 euploid blastocysts.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Euploid inner cell mass&lt;span&gt; (ICM) and trophectoderm transcriptome analysis examined in association with the timing of blastulation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Subjects&lt;/h3&gt;&lt;div&gt;Equivalent grade and maternal age-matched day 5 (n = 20) and day 7 (n = 20) surplus cryopreserved euploid blastocysts donated with informed patient consent.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intervention Exposure&lt;/h3&gt;&lt;div&gt;None.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Ribonucleic acid&lt;span&gt; (RNA) sequencing was used for transcriptome&lt;span&gt; analysis, followed by enriched pathways and gene ontology terms to determine functional relevance. Quantitative real-time polymerase chain reaction (PCR) was performed for targeted gene expression analysis and validation of differentially expressed genes identified by RNA sequencing.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;&lt;span&gt;&lt;span&gt;Timing of blastocyst development leads to significant differences in transcription for equivalent grade, maternal age-matched euploid blastocysts. Controlling for cellular lineage, 2,880 differentially expressed genes were identified in the day 7 ICM and 2,057 genes in the day 7 trophectoderm, compared with their equivalent grade day 5 counterparts. However, pathway enrichment was predominantly driven by downregulated gene expression in the ICM of day 7 blastocysts, impacting signal transduction pathways and genes involved in primitive &lt;/span&gt;endoderm development. Slower-developing blastocysts appear to face metabolic and &lt;/span&gt;endoplasmic reticulum stress&lt;span&gt;, leading to increased protein degradation in the ICM, irregular apoptotic activity, as well as compromised trophectoderm epigenetic regulation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;&lt;span&gt;The day 7 ICM transcriptome revealed disproportionate perturbations involving the &lt;/span&gt;downregulation&lt;span&gt; of many critical networks and genes required for embryogenesis, providing an array of molecular mechanisms responsible for developmental delay. With no significant impact on day 7 trophectoderm pathways, the reproductive potential of the blastocyst may be primarily driven by the molecular activity of the future fetal tissue lineage, thereby explaining the halving of live birth rates after euploid day 7 blastocyst transfers. Defining the network of embryonic pathways essential for developmental competence will allow for the future development of culture systems to support optimal extended culture for poor-prognosis patients.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Las alteraciones moleculares en el futuro linaje del tejido fetal se asocian con una blastulación euploide retardada.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objetivo&lt;/h3&gt;&lt;div&gt;Estudiar la actividad molecular subyacente que impulsa la reducción del potencial reproductivo de los blastocistos euploides de día 7.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Dise","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 759-768"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prematurely progesterone exposed endometrium waits for no embryo: whether measured once or cumulatively","authors":"Lea George M.D. ,&nbsp;Jason Franasiak M.D., H.C.L.D.","doi":"10.1016/j.fertnstert.2025.07.001","DOIUrl":"10.1016/j.fertnstert.2025.07.001","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 662-663"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144612822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progestin-primed ovarian stimulation: what new evidence shows about the role for artificial intelligence in clinical decision making","authors":"Joseph Chervenak M.D., M.B.A.,&nbsp;Gayathree Murugappan M.D.,&nbsp;Julia Kim M.D.,&nbsp;Debra Minjarez M.D.","doi":"10.1016/j.fertnstert.2025.07.013","DOIUrl":"10.1016/j.fertnstert.2025.07.013","url":null,"abstract":"","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"124 4","pages":"Pages 651-652"},"PeriodicalIF":7.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}